You are here

SBIR Phase I: Developing a Rapid Antibody Generation Platform for Emerging COVID-19 Variants

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 2033772
Agency Tracking Number: 2033772
Amount: $256,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: BT
Solicitation Number: N/A
Timeline
Solicitation Year: 2020
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-01
Award End Date (Contract End Date): 2021-08-31
Small Business Information
4000 Mason Road Fluke Hall, Suite 304
Seattle, WA 98195
United States
DUNS: 080919240
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Randolph Lopez Barrezueta
 (858) 405-7116
 rlopez@aalphabio.com
Business Contact
 Randolph Lopez Barrezueta
Phone: (858) 405-7116
Email: rlopez@aalphabio.com
Research Institution
N/A
Abstract

The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to improve and accelerate the development of antibody therapies to fight the COVID-19 pandemic. Antibody therapies are in development to target SARS-CoV-2, the virus r

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government